Latest Insider Transactions at Silk Road Medical Inc (SILK)
This section provides a real-time view of insider transactions for Silk Road Medical Inc (SILK). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Silk Road Medical Inc to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Silk Road Medical Inc's insiders and make more informed investment decisions.
Insider Transaction List
Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jun 17
2021
|
Elizabeth H Weatherman |
BUY
Grant, award, or other acquisition
|
Direct |
570
+0.23%
|
-
|
Jun 17
2021
|
Donald Zurbay |
BUY
Grant, award, or other acquisition
|
Direct |
570
+31.95%
|
-
|
Jun 17
2021
|
Jack W Lasersohn |
BUY
Grant, award, or other acquisition
|
Direct |
570
+9.65%
|
-
|
Jun 11
2021
|
Erica J. Rogers President and CEO |
SELL
Open market or private sale
|
Direct |
11,000
-7.71%
|
$517,000
$47.02 P/Share
|
Jun 11
2021
|
Erica J. Rogers President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
11,000
+7.16%
|
$11,000
$1.6 P/Share
|
Jun 03
2021
|
Jack W Lasersohn |
SELL
Open market or private sale
|
Direct |
5,427
-53.23%
|
$244,215
$45.6 P/Share
|
Jun 01
2021
|
Andrew S. Davis Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
6,324
-9.02%
|
$297,228
$47.23 P/Share
|
Jun 01
2021
|
Andrew S. Davis Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,324
+8.15%
|
$18,972
$3.17 P/Share
|
May 28
2021
|
Elizabeth H Weatherman |
SELL
Sale (or disposition) back to the issuer
|
Direct |
33,000
-11.95%
|
$1,650,000
$50.0 P/Share
|
May 26
2021
|
Lucas W. Buchanan COO/CFO |
SELL
Open market or private sale
|
Direct |
10,000
-5.21%
|
$470,000
$47.56 P/Share
|
May 26
2021
|
Lucas W. Buchanan COO/CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+4.96%
|
$200,000
$20.0 P/Share
|
May 20
2021
|
Erica J. Rogers President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
420
+0.32%
|
$16,800
$40.38 P/Share
|
May 20
2021
|
Andrew S. Davis Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
420
+1.31%
|
$16,800
$40.38 P/Share
|
May 20
2021
|
Lucas W. Buchanan COO/CFO |
BUY
Grant, award, or other acquisition
|
Direct |
420
+0.23%
|
$16,800
$40.38 P/Share
|
May 11
2021
|
Erica J. Rogers President and CEO |
SELL
Open market or private sale
|
Direct |
11,000
-7.71%
|
$528,000
$48.65 P/Share
|
May 11
2021
|
Erica J. Rogers President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
11,000
+7.16%
|
$11,000
$1.6 P/Share
|
May 05
2021
|
Lucas W. Buchanan COO/CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+2.68%
|
$5,000
$1.6 P/Share
|
May 03
2021
|
Andrew S. Davis Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
6,324
-16.84%
|
$392,088
$62.05 P/Share
|
May 03
2021
|
Andrew S. Davis Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,324
+14.41%
|
$6,324
$1.6 P/Share
|
Apr 28
2021
|
Lucas W. Buchanan COO/CFO |
SELL
Open market or private sale
|
Direct |
10,000
-2.71%
|
$610,000
$61.43 P/Share
|
Apr 28
2021
|
Lucas W. Buchanan COO/CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+2.6%
|
$160,000
$16.08 P/Share
|
Apr 12
2021
|
Erica J. Rogers President and CEO |
SELL
Open market or private sale
|
Direct |
11,000
-3.88%
|
$539,000
$49.73 P/Share
|
Apr 12
2021
|
Erica J. Rogers President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
11,000
+3.62%
|
$11,000
$1.6 P/Share
|
Apr 05
2021
|
Andrew S. Davis Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
660
-2.07%
|
$33,660
$51.16 P/Share
|
Apr 01
2021
|
Andrew S. Davis Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
6,324
-16.54%
|
$316,200
$50.86 P/Share
|
Apr 01
2021
|
Andrew S. Davis Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,324
+14.2%
|
$6,324
$1.6 P/Share
|
Mar 29
2021
|
Lucas W. Buchanan COO/CFO |
SELL
Open market or private sale
|
Direct |
10,000
-2.69%
|
$460,000
$46.73 P/Share
|
Mar 29
2021
|
Lucas W. Buchanan COO/CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+2.56%
|
$120,000
$12.15 P/Share
|
Mar 11
2021
|
Erica J. Rogers President and CEO |
SELL
Open market or private sale
|
Direct |
11,000
-7.71%
|
$572,000
$52.96 P/Share
|
Mar 11
2021
|
Erica J. Rogers President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
11,000
+7.16%
|
$11,000
$1.6 P/Share
|
Mar 02
2021
|
Erica J. Rogers President and CEO |
SELL
Open market or private sale
|
Direct |
1,651
-0.61%
|
$92,456
$56.62 P/Share
|
Mar 01
2021
|
Erica J. Rogers President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,692
-1.27%
|
$94,752
$56.75 P/Share
|
Mar 01
2021
|
Erica J. Rogers President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
21,700
+14.0%
|
-
|
Mar 01
2021
|
Lucas W. Buchanan COO/CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
893
-0.5%
|
$50,008
$56.86 P/Share
|
Mar 01
2021
|
Lucas W. Buchanan COO/CFO |
BUY
Grant, award, or other acquisition
|
Direct |
11,300
+5.98%
|
-
|
Mar 01
2021
|
Richard Ruedy EVPClin&Reg.Affairs&QA |
SELL
Payment of exercise price or tax liability
|
Direct |
340
-0.26%
|
$19,380
$57.12 P/Share
|
Mar 01
2021
|
Richard Ruedy EVPClin&Reg.Affairs&QA |
BUY
Grant, award, or other acquisition
|
Direct |
4,300
+3.15%
|
-
|
Mar 01
2021
|
Andrew S. Davis Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
508
-1.57%
|
$28,448
$56.95 P/Share
|
Mar 01
2021
|
Andrew S. Davis Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,300
+26.65%
|
-
|
Mar 01
2021
|
Andrew S. Davis Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
7,472
-27.4%
|
$418,432
$56.49 P/Share
|
Mar 01
2021
|
Andrew S. Davis Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,472
+21.5%
|
$7,472
$1.46 P/Share
|
Feb 26
2021
|
Lucas W. Buchanan COO/CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
917
-0.55%
|
$51,352
$56.63 P/Share
|
Feb 26
2021
|
Lucas W. Buchanan COO/CFO |
BUY
Grant, award, or other acquisition
|
Direct |
2,676
+1.57%
|
-
|
Feb 26
2021
|
Richard Ruedy EVPClin&Reg.Affairs&QA |
BUY
Grant, award, or other acquisition
|
Direct |
1,047
+0.78%
|
-
|
Feb 26
2021
|
Richard Ruedy EVPClin&Reg.Affairs&QA |
SELL
Payment of exercise price or tax liability
|
Direct |
350
-0.27%
|
$19,600
$56.7 P/Share
|
Feb 26
2021
|
Andrew S. Davis Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,828
+5.34%
|
-
|
Feb 26
2021
|
Andrew S. Davis Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
522
-1.68%
|
$29,232
$56.59 P/Share
|
Feb 24
2021
|
Lucas W. Buchanan COO/CFO |
SELL
Open market or private sale
|
Direct |
10,000
-1.96%
|
$530,000
$53.64 P/Share
|
Feb 24
2021
|
Lucas W. Buchanan COO/CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+1.89%
|
$80,000
$8.38 P/Share
|
Feb 17
2021
|
Lucas W. Buchanan COO/CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+5.73%
|
$10,000
$1.6 P/Share
|